Physician profile
Matthew Gordon
NPI 1922391952
$5,484.67
in general payments reported to CMS, 2019-2025
26 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.88 · 2022: $36.01 · 2023: $239 · 2024: $3,520 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,285 · Food and Beverage: $2,038 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,285.00 |
| Food and Beverage | $2,037.79 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $3,285.00 | 2024 | Zemaira |
| Astrazeneca Pharmaceuticals LP | $350.52 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $339.43 | 2021-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $253.53 | 2024-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $166.14 | 2022-2025 | Aralast |
| Inspire Medical Systems, INC. | $155.12 | 2023-2025 | Inspire |
| Genzyme Corporation | $140.46 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $81.21 | 2025 | Purified Cortrophin Gel |
| Insmed, INC. | $72.36 | 2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $69.82 | 2025 | Dupixent |
| Amgen INC. | $58.81 | 2024-2025 | Tezspire |
| Verona Pharma, INC. | $55.94 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $51.27 | 2024-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $49.94 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $47.58 | 2024 | Lumryz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $47.52 | 2025 | Zepbound |
| Grifols USA, LLC | $46.98 | 2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $36.93 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.00 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.82 | 2025 | Jascayd |
| Novartis Pharmaceuticals Corporation | $24.00 | 2025 | |
| Novo Nordisk INC | $19.98 | 2025 | Wegovy |
| La Jolla Pharmaceutical Company | $18.79 | 2022 | |
| Viatris Specialty LLC | $16.67 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $15.62 | 2025 | Winrevair |
| Philips North America LLC | $15.23 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.